Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX – Research Report), Replimune Group (REPL – Research Report) and Gilead Sciences (GILD – Research Report).
Amneal Pharmaceuticals (AMRX)
In a report issued on July 3, Balaji Prasad from Barclays maintained a Buy rating on Amneal Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Monday at $3.05.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of
Amneal Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $3.50.
See the top stocks recommended by analysts >>
Replimune Group (REPL)
Barclays analyst Peter Lawson maintained a Buy rating on Replimune Group on July 3 and set a price target of $50.00. The company’s shares closed last Monday at $21.92.
According to TipRanks.com, Lawson is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group with a $54.63 average price target, implying a 134.5% upside from current levels. In a report issued on June 27, BTIG also maintained a Buy rating on the stock with a $60.00 price target.
Gilead Sciences (GILD)
Barclays analyst Carter Gould maintained a Hold rating on Gilead Sciences on July 3 and set a price target of $84.00. The company’s shares closed last Monday at $76.72.
According to TipRanks.com, Gould is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $93.00 average price target, a 22.0% upside from current levels. In a report issued on June 23, RBC Capital also reiterated a Hold rating on the stock with a $88.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMRX:
